Market Volatility Insights – 02.10.2024 18:34by Alex Insight 02.10.2024Discover key insights on market volatility amidst social media trends and economic data.
ETFSwap Challenges Solana and Dogecoin in Marketby John Darbie 14.09.2024ETFSwap aims to surpass Solana and Dogecoin, climbing into the crypto top 10 and attracting investors with its innovative platform.
Dogecoin Poised for 900% Surge, Analyst Predictsby John Darbie 10.08.2024Analyst highlights 7 key factors that could lead to a 900% Dogecoin surge, including a breakout and Musk's influence.
Tether Plans to Double Staff by 2025 for Complianceby Mark Eisenberg 09.08.2024Tether aims to double its workforce by mid-2025 to enhance compliance and finance operations amid growing regulatory scrutiny.
UBS: Market Reaction Overblown, ‘Quality’ Stocks to Outperformby Mark Eisenberg 06.08.2024"UBS says market fears may be overblown, citing moderate data and volatility. Sees potential in 'quality' stocks, utilities, and positive ...
Top 10 New Cryptocurrencies to Watch in 2024 | Bankrateby Mark Eisenberg 06.08.2024Discover the top 10 new cryptocurrencies of 2024 capturing traders’ interest despite market risks. Is it worth investing in these ...
Crypto Trader Faces $2M Loss in 30 Days with PEPEby John Darbie 26.06.2024Crypto trader 0x8376 suffers $2M loss in 30 days trading PEPE, highlighting the risks of meme coins and the importance ...
Cryptocurrency Prices Today: Bitcoin Dips Below $63,000by John Darbie 24.06.2024Crypto Market Crash: Bitcoin drops below $63,000; major altcoins like Ethereum, Dogecoin, and Solana also see significant declines.
ETH Price Prediction: What to Expect on June 24, 2024by Terry Bingman 24.06.2024Discover Ethereum's 72-hour price forecast with key insights into historical data, market trends, and predictive analysis for informed trading decisions.
Esperion Stock Downgraded Amid Merck’s Competitive Pressureby Mark Eisenberg 20.06.2024Esperion's stock downgraded by BofA due to rising competition from Merck's PCSK9 inhibitors. Analysts weigh in on efficacy and market ...